Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?

Area of Science:

• Endocrinology
• Metabolism
• Pharmacology

Background:

• Levothyroxine (LT4) is the standard treatment for hypothyroidism.
• Some patients remain symptomatic despite normalized thyrotropin levels on LT4 therapy.
• The reasons for persistent symptoms and the role of combination therapy are not fully understood.

Purpose of the Study:

• To explore evidence of abnormal thyroid hormone (TH) metabolism in LT4-treated patients.
• To provide a rationale for why some patients perceive LT4 therapy as ineffective.
• To discuss the potential role of combination therapy with LT4 and liothyronine (LT3).

Main Methods:

• Literature review of primary and review articles.
• Searches conducted on PubMed and Google Scholar.
• Inclusion of authors' prior knowledge on the subject.

Main Results:

• Most LT4-treated patients show decreased serum T3/T4 ratio and lower serum T3 levels.
• In at least 15% of cases, serum T3 levels are below normal, potentially impairing TH action.
• Persistent symptoms like fatigue and cognitive issues may occur in a subset of patients, possibly due to genetic or immunologic factors.

Conclusions:

• Physicians should consider LT4 and LT3 combination therapy for symptomatic patients with metabolic abnormalities despite normalized thyrotropin.
• Further clinical trials are needed to investigate symptomatic patients, genetic factors, and comorbidities.
• Research should focus on identifying differences between monotherapy and combination therapy in specific patient populations.